Implant-Based Slow Release of Molecules to Prevent Glioblastoma Recurrence

TL;DR Summary
The article discusses a novel implantable wafer system called CANDI that delivers immunostimulatory small molecules to reprogram immunosuppressive myeloid cells in glioblastoma, leading to long-term survival and prevention of tumor recurrence in mouse models, with promising implications for human treatment.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
58 min
vs 58 min read
Condensed
100%
11,590 → 40 words
Want the full story? Read the original article
Read on Nature